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Background: Polycystic ovary syndrome (PCOS) is associated with an adverse
cardiovascular risk profile including a prothrombotic state. Exenatide has been shown
to be effective at improving insulin sensitivity and weight loss in PCOS; therefore this
study was undertaken to assess its effects on weight, endothelial function, inflammatory
markers, and fibrin structure/function in overweight/obese women with PCOS.
Methods: Thirty overweight/obese anovulatory women with all 3 Rotterdam criteria
received exenatide 5 mcg bd for 4 weeks then 10 mcg bd for 12 weeks. The primary
outcome was change in weight; secondary outcomes were changes in endothelial
function [Reactive Hyperemia-Peripheral Arterial Tonometry (RH-PAT)], serum endothelial
markers (ICAM-1, VCAM-1, E-selectin, and P-selectin), change in inflammation (hsCRP),
and alteration in clot structure and function [maximum absorbance (MA), and time from
full clot formation to 50% lysis (LT)].
Results: Twenty patients completed the study. Exenatide reduced weight 111.8 ± 4.8
to 108.6 ± 4.6 kg p = 0.003. Serum endothelial markers changed with a reduction in
ICAM-1 (247.2 ± 12.9 to 231.3 ± 11.5 ng/ml p = 0.02), p-selectin (101.1 ± 8.2 to
87.4 ± 6.6 ng/ml p = 0.01), and e-selectin (38.5 ± 3.3 to 33.6 ± 2.6 ng/ml p = 0.03),
without an overt change in endothelial function. Inflammation improved (CRP; 8.5 ± 1.4
to 5.6 ± 0.8 mmol/L p = 0.001), there was a reduction in clot function (LT; 2,987 ± 494
to 1,926 ± 321 s p = 0.02) but not clot structure.
Conclusion: Exenatide caused a 3% reduction in weight, improved serum markers
of endothelial function, inflammation, and clot function reflecting an improvement in
cardiovascular risk indices in these women with PCOS. This suggests exenatide could
be an effective treatment for obese women with PCOS.
Clinical Trial Registration: ISRCTN81902209.
Keywords: polycystic ovary syndrome, exenatide, cardiovascular risk, endothelial function, inflammation, blood
clot function, GLP-1 receptor agonists
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INTRODUCTION
Polycystic ovary syndrome (PCOS) is a common condition
affecting 10% of women of reproductive age (1) and is
characterized by chronic anovulation and hyperandrogenism.
Women with PCOS have an adverse cardiovascular risk
profile including obesity, hypertension, dyslipidaemia, impaired
glucose tolerance, and ischemic heart disease (2–4). Endothelial
dysfunction is an early marker of atherosclerosis and has been
shown to be present in women with PCOS in some (5–7) but not
in all studies (8, 9). Treatments resulting in an improvement in
endothelial function may slow the progression of atherosclerosis
and therefore may reduce the risk of future cardiovascular events
(10) and an improvement of endothelial function has been
shown with weight loss and metformin treatment in women
with PCOS (11). Serological markers of endothelial function
include endothelin-1 that is reported to be elevated in PCOS
(12), but decreased after 6 months metformin therapy (12). The
endothelial function marker intercellular adhesion molecule-1
(ICAM-1) has also been reported to be elevated in PCOS (13).
Inflammatory markers have been noted to be higher in
patients with PCOS; C-reactive protein (CRP) has consistently
been shown to be greater in PCOS than controls (14, 15). PCOS
has been confirmed to be a prothrombotic state compared to
controls (16) with raised levels of plasminogen activator inhibitor
1 (PAI-1) activity and fibrinogen being reported.
Abnormal clot structure and function contributes to the
prothrombotic state; clots composed of a compact structure with
thin fibers and small pores are associated with early and more
severe cardiovascular disease (17). Clot structure is denser and
less porous in individuals with type 2 diabetes (18) compared
to controls, and has been shown to be less permeable in healthy
relatives of people with premature coronary artery disease (19).
Metformin has been shown to be beneficial in altering clot
structure and function in patients with type 2 diabetes (20) that
may reflect reduced insulin resistance.
Exenatide, an incretin mimetic, is a glucagon like polypeptide
(GLP-1) analog used in the treatment of type 2 diabetes
(21). It has several methods of action including enhancing
glucose-dependent insulin synthesis from pancreatic beta cells,
decreasing glucagon production, and slowing gastric emptying
time. GLP-1 analogs have shown to reduce weight (22–27),
reduce hyperandrogenism (22, 27) and improve menstrual
cyclicity (22, 25) in women with PCOS. In one study in
patients with PCOS, exenatide with or without metformin
was given for 6 months and showed an improvement in
menstrual frequency and hyperandrogenism (22). There was
a reduction in the anti-inflammatory marker adiponectin, but
no change in CRP, interleukin-6 (IL-6), or tumor-necrosis
factor-α (TNFα). In a study examining obese patients with
type 2 diabetes exenatide, given for 12 weeks was shown to
exert a potent anti-inflammatory effect at the cellular and
molecular level (28).
We therefore hypothesized that exenatide would exert a
direct effect on endothelial function, inflammatory markers and
blood clot structure and function in overweight/obese women
with PCOS.
PATIENTS AND METHODS
An open labeled study was undertaken using exenatide 5
micrograms twice daily for 1 month followed by exenatide 10
µg twice daily for 3 months. The diagnosis of PCOS was based
on all three diagnostic criteria of the Rotterdam consensus
being present for each patient to reduce the heterogeneity
of the diagnosis, namely clinical, and biochemical evidence
of hyperandrogenemia [Ferriman-Gallwey score >8; free
androgen index (FAI) >4], oligomenorrhoea or amenorrhea,
and polycystic ovaries on transvaginal ultrasound. Non-classical
21-hydroxylase deficiency, hyperprolactinaemia, Cushing’s
disease, and androgen-secreting tumors were excluded by
appropriate tests. Subjects had no concurrent illness, were not
on any prescription or over-the-counter medication that was
likely to affect insulin sensitivity, lipids, or ovarian function
including hormonal contraceptives for the preceding 6 months.
Subjects were not planning to conceive and were using barrier
contraception. Subjects were advised not to change their
lifestyle, including physical activity, or dietary habits, during the
study period.
Thirty patients (mean age 27 ± 4 years) who fulfilled
both inclusion and exclusion criteria were given exenatide.
Compliance with treatment was calculated by determining the
amount of exenatide in the pens returned at the next clinic visit
(2 and 4 months).
All subjects gave written informed consent in accordance with
the Declaration of Helsinki. The protocol was approved by the
Leeds East Local Research Ethics committee.
Clinical and fasting biochemical assessments were performed
at baseline and at the end of the 4-month period. The primary
endpoint of the study was a change in weight, and the secondary
endpoints were changes in endothelial function, inflammation,
and clot structure.
Fasting venous blood was collected into serum gel and fluoride
oxalate tubes. Samples were separated by centrifugation at 2,000
× g for 15min at 4◦C, and the aliquots stored at −20◦C. Serum
testosterone was measured by liquid chromatography/mass
spectroscopy on an Acquity UPLC system coupled to a Quattro
Premier XE mass spectrometer (Waters, Manchester, UK).
Sex hormone binding globulin (SHBG) was measured by an
immunometric assay with fluorescence detection on the DPC
Immulite 2000 analyzer using the manufacturer’s recommended
protocol (upper limit of the reference range 2.0 nmol/l). The
FAI was calculated as the total testosterone × 100/SHBG.
Total cholesterol, triglycerides, and high-density lipoprotein
cholesterol (HDL-C) levels were measured enzymatically using
a Synchron LX20 analyzer (Beckman-Coulter, High Wycombe,
UK). Low-density lipoprotein cholesterol (LDL-C) was calculated
using the Friedewald equation. Serum insulin was assayed
using a competitive chemiluminescent immunoassay performed
on the DPC Immulite 2000 analyzer (Euro/DPC, Llanberis,
UK). The analytical sensitivity of the insulin assay was 2
µU/ml, the coefficient of variation was 6%, and there was
no stated cross-reactivity with proinsulin. Plasma glucose
was measured using a Synchron LX 20 analyzer (Beckman-
Coulter), using the manufacturer’s recommended protocol. The
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coefficient of variation for the assay was 1.2% at a mean
glucose value of 5.3 mmol/L during the study period. The
insulin resistance was calculated using the homeostasis model
assessment for insulin resistance (HOMA) method [HOMA-
IR = (insulin x glucose)/22.5]. Alanine aminotransferase was
measured on the Unicel R© DxC 80 analyser (Beckamn-Coulter,
High Wycome, UK).
The serum concentrations of serum intercellular adhesion
molecule 1 (ICAM-1), serum vascular cell adhesion molecule
1 (sVCAM-1), and sE-selectin were measured by commercially
available quantitative ELISA (R&D Systems, USA) according to
the manufacturer’s instructions.
Reactive hyperemia peripheral arterial tonometry (RH-PAT)
is a non-invasive technique to assess peripheral microvascular
endothelial function by measuring changes in digital pulse
volume during reactive hyperemia. The RH-PAT data were
analyzed by a computer in an operator-independent manner as
previously described (29). The RH-PAT index was calculated as
the ratio of the average amplitude of the PAT signal over a 1-
min time interval starting 1min after cuff deflation divided by
the average amplitude of the PAT signal of a 3.5-min time period
before cuff inflation (baseline). This was carried out after 12 h
fast at 9 a.m. in a stable environment (20◦C air conditioned room
having allowed for an equilibrium period of 15min with dimmed
lights according to manufacturer’s instructions) (29).
Clot structure and fibrinolysis measurements were conducted
using turbidity and lysis measurements as previously described
(30). In brief, for turbidity measurements, plasma samples (25
µl) were added to a 96 well-Greiner plate (in duplicate) with 50
mmol−1 Tris, 100 mmol−1 NaCl pH 7.4 (75 µl). Activation mix
(50µl) containing 0.045Uml−1 human thrombin (Calbiochem),
and 22.5 mmol−1 calcium in assay buffer was added to each
column with a multi-channel pipette at 10-s intervals. Plates were
shaken and read at 340 nm every 12 s for 60min in an ELx-808 IU
ultramicroplate reader (BIO-TEK Instruments INC, USA).
For lysis measurements, the same procedure was applied, but
with the addition of 333 ng ml−1 tissue plasminogen activator
(tPA) (75 µl) (Technoclone, Vienna, Austria). A number of
parameters were subsequently analyzed including final turbidity
(FT), time from initiation of clot formation to 50% lysis (LT1)
and time from start of clot formation to 50% lysis (LT2).
Statistical Analysis
The sample size was based on the study of Elkind-Hirsch et al
treating women with PCOS on the effect of exenatide on weight
loss in women with PCOS (22). Using nQuery advisor sample
size software, for 80% power and a significance level of 5%, a
sample size of 20 was calculated. Adjusting for a possible 30%
dropout rate due to side effects reported (22) a total of 30 patients
were recruited.
A comparison between the groups at baseline and follow
up was carried out using the paired t-test for biochemical data
and clinical observations. The Wilcoxon signed rank test was
applied to biochemical data that violated the assumptions of
normality when tested using the Kolmogorov–Smirnov test, and
associations used Pearson’s correlation or Spearman’s correlation
as appropriate. Statistical analysis was performed using SPSS for
Windows NT, version 18.0 (SPSS Inc., Chicago, IL). Data are
reported as mean± SEM.
RESULTS
Twenty patients aged 26 ± 4 years completed the study. One
patient became pregnant during the study, and six patients
withdrew due to side effects [nausea, vomiting, and dizziness
(two patients on the 5 µg twice daily dose and four patients on
the 10 µg twice daily dose)]. Two patients were withdrawn due
to poor compliance during the first month and one patient was
lost to follow up. The pregnancy was followed to term with no
maternal or fetal complications.
The mean weight of the women at baseline was 110.0 ±
3.4 kg with BMI 40.4 ± 1.3 kg/m2 [3 women were overweight
(BMI 26–29) whilst 27 were obese (BMI 30 or greater)] Systolic
blood pressure was 119.7 ± 2.2 mmHg and diastolic was 71.5 ±
1.6 mmHg.
There was a significant reduction in weight from 111.8 ± 4.8
to 108.6 ± 4.6 kg (p = 0.003) and BMI 41.0 ± 1.9 to 39.8 ± 1.8
kg/m2 (p = 0.005). There was no effect on waist circumference
but there was a reduction in hip circumference. Blood pressure
was unaffected by the exenatide treatment (Table 1).
There was no change in FAI or SHBG at the completion of
the study.
There was no effect on total cholesterol, HDL or LDL-
cholesterol but there was an improvement in triglycerides 1.3
± 0.1 to 1.2 ± 0.1 mmol/L p = 0.04. There was no difference
in glucose, insulin and HOMA-IR comparing before and after
exenatide treatment (Table 2).
Endothelial function determined by RH-PAT was unchanged
[RH-PAT (1.67 ± 0.1 to 1.49 ± 0.1 p = 0.06)]; however, the
surrogate measures of endothelial function improved with a
reduction in ICAM-1 (247.2 ± 12.9 to 231.3 ± 11.5 ng/ml p =
0.02), p-selectin (101.1 ± 8.2 to 87.4 ± 6.6 ng/ml p = 0.01), and
e-selectin (38.5± 3.3 to 33.6± 2.6 ng/ml p= 0.03). There was no
change in VCAM-1.
There was an improvement in CRP from 8.5± 1.4 to 5.6± 0.8
mmol/L p= 0.001.
For clot formation there was a reduction in time from full clot
formation to 50% lysis (LT) from 2,987 ± 494 to 1,926 ± 321 s
p = 0.02, but exenatide did not have an effect on the maximum
absorbance (MA).
There was a correlation between a change in ICAM and
triglycerides (r = −0.59 p = 0.02), change in p-selectin and hip
circumference (r = 0.61 p = 0.009) and change in CRP and
insulin/HOMA (r =−0.57 p= 0.02 r =−0.49 p= 0.047). There
was also a correlation between change in LT and systolic blood
pressure (r =−0.63, p= 0.03).
The study time was too short to assess an effect
on menstruation.
DISCUSSION
This study confirmed the modest weight loss that could be
achieved with exenatide in overweight women with PCOS
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TABLE 1 | Physical characteristics for the 20 subjects with PCOS before and after
exenatide therapy (mean ± SD).
Baseline N = 20 After therapy N = 20 p-value
Weight (kg) 111.8 ± 4.8 108.6 ± 4.6 0.003
BMI (kg/m2) 41.0 ± 1.9 39.8 ± 1.8 0.005
Waist (cm) 120.2 ± 3.6 118.1 ± 4.1 0.31
Hip (cm) 129.3 ± 3.1 126.3 ± 3.2 0.001
Systolic blood pressure
(mmHg)
118.1 ± 2.9 119.2 ± 3.2 0.60
Diastolic blood pressure
(mmHg)
73.0 ± 1.8 73.3 ± 2.3 0.86
RH-PAT 1.67 ± 0.1 1.49 ± 0.1 0.06.
BMI, body mass index; RH-PAT, reactive hyperemia-peripheral arterial tonometry.
TABLE 2 | Laboratory data for the 20 subjects with PCOS before and after
exenatide therapy.
Baseline n = 20 After therapy n = 20 p-value
ALT (IU/L) 32.5 ± 2.9 32.2 ± 3.3 0.84
CRP (mmol/L) 8.5 ± 1.4 5.6 ± 0.9 0.001
TC (mmol/L) 4.4 ± 0.2 4.5 ± 0.2 0.30
HDL-C (mmol/L) 1.08 ± 0.10 0.98 ± 0.07 0.22
LDL-C (mmol/L) 3.03 ± 0.14 2.98 ± 0.17 0.67
Triglycerides (mmol/L) 1.34 ± 0.14 1.17 ± 0.11 0.037
Fasting glucose (mmol/L) 5.0 ± 0.1 4.8 ± 0.1 0.24
Insulin (uIU/mL) 18.4 ± 2.7 18.8 ± 2.8 0.90
HOMA-IR 4.13 ± 0.64 4.07 ± 0.67 0.94
FAI (%) 15.8 ± 1.9 14.2 ± 1.9 0.36
SHBG (nmol/L) 23.4 ± 1.7 25.1 ± 1.9 0.36
VCAM-1 (ng/ml) 2284.3 ± 75.4 2329.8 ± 77.0 0.42
ICAM-1 (ng/ml) 247.2 ± 12.9 231.3 ± 11.5 0.02
E-selectin (ng/ml) 38.5 ± 3.3 33.6 ± 2.6 0.03
P-selectin (ng/ml) 101.1 ± 8.2 87.4 ± 6.6 0.01
LT1 (s) 3506 ± 489 2469 ± 307 0.02
LT2 (s) 2987 ± 494 1926 ± 321 0.02
ALT, alanine aminotransferase; CRP, high sensitivity-C-reactive protein; TC, total
cholesterol; LDL, low density lipoproteins; HDL, high density lipoproteins; HOMA-IR,
homeostatic model assessment of Insulin resistance; FAI, free androgen index; SHBG, sex
hormone binding globulin; VCAM, vascular cell adhesion molecule 1; ICAM, intercellular
adhesion molecule 1; LT, lysis time. Data are presented as mean ± SD.
with improved serum markers of endothelial function,
inflammation, and improved clot function, all of which
reflected an improvement in cardiovascular risk indices in these
women with PCOS.
In accord with a previous study on GLP-1 analogs (31),
exenatide was found to reduce weight (an average of 3.4 kg
over 16 weeks). This is consistent with values for weight loss in
patients with diabetes being treated with exenatide [between 2
and 6 kg (32) for a duration of exenatide between 90 and 365 days
(33)]. In PCOS patients, the mean weight loss was 3.2 kg after a
total of 16 weeks of exenatide treatment (5 mcg bd for 4 weeks
then 10 mcg bd for 12 weeks). The patients in our study lost
more weight than previously quoted that could be explained by
the patients in our study having a higher BMI at baseline (average
BMI 41.0 kg/m2) compared to other studies. The study was
too short to determine changes in menstrual frequency though
increased menstrual frequency with exenatide has been shown by
others (34).
The endothelium is crucial in regulating vascular function
by modulating tone, growth, homeostasis, and inflammation
(35). The endothelium has several roles including endothelium
dependent vasodilatation, regulation of cellular adhesion
molecules, and releasing key homeostatic regulatory molecules
(36). The cellular adhesion markers have previously been shown
to be raised in PCOS (12, 13) and therefore the reductions
of ICAM-1, e-selectin and p-selectin that were seen in our
study may suggest the mechanism of how exenatide improves
the adverse cardiovascular risk profile in PCOS. However, the
inconsistency between the results of endothelial function and
serum endothelial markers seen in our study is in accord with
that reported by others in PCOS (5–9). There was a positive
change in the endothelial markers, but whilst there was a trend,
there was the inconsistency that endothelial function did not
significantly improve when measured by the Endopat2000. This
may highlight that the serological cellular adhesion molecules
may be modifiable with 16 weeks of exenatide treatment
whereas RH-PAT may require more time to show a significant
change, and clarification of these functional findings with longer
studies involving serial measurement of the serum endothelial
markers are required. The correlation of decreased ICAM-1
with triglycerides and p-selectin with hip circumference is in
accord with their relationship with metabolic syndrome and
their reduction that reflected the weight loss (37, 38).
Another explanation for the inconsistency in endothelial
function may be the different methods used to calculate
endothelial function, although an advantage of the Endopat2000
is that it is operator independent (29). Exenatide has been shown
to have a short term benefit on endothelial function in patients
with type 2 diabetes (39) (using RH-PAT) when measured after
one injection of exenatide or placebo but long term effects on
endothelial function have not been reported.
Endothelial function is an early marker of cardiovascular
disease whereas blood clot structure and function is a late marker.
A novel finding in this study was that exenatide resulted in a
reduction of time from full clot formation to 50% lysis (LT)
which may be relevant as an increase in LT has been shown to be
associated with cardiovascular risk (30); these findings need to be
confirmed as this may add a new facet to the cardiovascular risk
that these women have. The correlation of LT to systolic blood
pressure likely reflects the complex relationship of the fibrinolytic
potential and arterial structure and function (40). An adverse
cardiovascular risk profile has been demonstrated in PCOS(2)
although evidence for increased cardiovascular mortality is not
well-established (41). More angiographic coronary artery disease
and worsening cardiovascular event free survival has been shown
in postmenopausal women with a history of PCOS compared to
those without a PCOS history (42).
An improvement in inflammation was seen in our study with
a significant reduction in both CRP and serum triglycerides.
This is in accord with reports of exenatide use in patients with
type 2 diabetes (43, 44), but the reduction in CRP was not seen
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in a previous study with PCOS patients (22); however, baseline
CRP was measured using different methods between the two
studies and cannot be compared, though our patients had a
higher level of triglycerides (4.4 vs. 1.16 nmol/L) that may explain
the significant reduction. Insulin resistance correlated with the
reduction in CRP as well-described by others (45).
In contrast to a previous study with exenatide our study
showed there was no reduction in total testosterone or HOMA
(22) that may be explained by the difference in duration of the
study (our study was shorter at 4 months compared to 6 months)
and the different patient population studied.
The weakness of this study is the high drop-out rate
which largely was due to side effects of the medication
(namely nausea and vomiting), however the withdrawal rate
was similar to that reported in a previous study (22) of 30%.
An additional limitation was the lack of a group of controls
such as obese women not affected by PCOS to determine
whether those changes reported were independent of the
PCOS phenotype.
In summary, this study has shown that exenatide is
effective in improving the parameters of adverse cardiovascular
risk in obese women with PCOS. There was no change
of endothelial function by direct measurement that may
indicate that surrogate markers do not reflect endothelial
change in PCOS.
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